Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Bacteria Builds Up as Progress Lags

By R&D Editors | May 29, 2012

Drug resistance and patent expiries are demanding that the antibacterial drug market moves forwards soon, but a current lack of interest from pharmaceutical companies has led to market stagnation, according to a new report by healthcare experts GBI Research.

The new report shows that while hospital hygiene campaigns to conquer MRSA encourage public awareness of the importance of antibacterials, academic researchers are struggling to secure interest from commercial giants who can push new discoveries through the clinical pipeline process.

One major issue currently threatening the antibacterials market is the development of drug resistance. Increasing use of antibacterials is leading bacteria to evolve over time and develop resistance to the drugs used to treat the conditions they cause. As antibiotic prescription increases, the rate of resistance is also seen to increase.

Escherichia coli, a major cause of urinary tract infections (UTIs), has become increasingly resistant to fluoroquinolones, while multi-drug resistant tuberculosis (MDR-TB) is on the rise as well.

Despite the rising unmet need caused by drug resistance, a lack of interest in developing the market is present, possibly due to recent slumps in drug prices and increased competition. Several popular branded antibacterial products have recently lost their patent exclusivity, or are expected to lose it soon. For example, the recent patent expiry of Johnson and Johnson’s blockbuster antibiotic Levaquin led to a dip in overall market revenue, as this drug is used in multiple indications. The high proportion of cheaper generic products has led to a reduction of the average annual cost of therapy and fragmented the market.

As a consequence, the therapy pipelines for the bacterial diseases outlined in GBI Research’s report are relatively weak. Many drugs are in development by academic institutions currently lacking the industrial backing to bring them to market. While alliances are forming between these institutions and pharmaceutical companies, this has a limited capacity to increase market revenues at the moment and investments remain unattractive for many branded drug manufacturers.

However, the future may hold some developments for antibacterial research, with an increase in revenue predicted for 2013 following the market’s slow recovery from the patent expiry of Levaquin. The market is expected to generate annual revenues of $12.7 billion by 2017.

Date: May 29, 2012
Source: GBI Research

Related Articles Read More >

Certara’s COVID vaccine model is focus of Episode 8 of R&D 100 – The Podcast
New dangers in the woods — and the hope that research offers us
PerkinElmer participating at Bio-IT World Conference & Expo
Nalu Medical’s mIPG is focus of Episode 7 of R&D 100 – The Podcast
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2022 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars